Access the full text.
Sign up today, get DeepDyve free for 14 days.
L. Levin (1991)
Myocardial infarction : Costs and benefits of prevention and treatments
(1996)
Acute myocardial infarction register 1987±94. Stockholm: Centre for Epidemiology, The National Board of Health and Welfare
A. Térent, L. Marké, K. Asplund, B. Norrving, E. Jonsson, P. Wester (1994)
Costs of Stroke in Sweden A National PerspectiveStroke, 25
Andersson Andersson, Kartman Kartman (1995;)
The cost of angina pectoris in Sweden.Pharmacoeconomics, 8
Johannesson Johannesson (1995;)
The Cost Effectiveness of Hypertension Treatment in Sweden.Pharmacoeconomics, 7
Ursula Hass, Jan Persson, Håkan Brodin, Ingrid Fredén-Karlsson, Jan-Edvin Olsson, Inger Berg (1995)
Assessment of Rehabilitation Technologies in Stroke: Outcomes and CostsInternational Journal of Technology Assessment in Health Care, 11
T. Ellis (1995)
Inflammatory bowel disease: genes or germs?Journal of Internal Medicine, 238
B. Bloom, Banta Hd, P. Gross, Jorge Peña-Mohr, J. Sisk, B. Stocking (1989)
The Swedish Council on Technology Assessment in Health CareInternational Journal of Technology Assessment in Health Care, 5
Ulf Persson, Raymunda Sliverberg, B. Lindgren, B. Norrving, G. Jadbäck, B. Johansson, Britt-Inger Puranen (1990)
Direct Costs of Stroke for a Swedish PopulationInternational Journal of Technology Assessment in Health Care, 6
Claes Gustafsson, K. Asplund, M. Britton, B. Norrving, B. Olsson, L. Marké (1992)
Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective.British Medical Journal, 305
e-mail: [email protected])
E. Mills, M. Thompson (1978)
The economic costs of stroke in Massachusets.The New England journal of medicine, 299 8
Statens Metodik (1995)
Moderately elevated blood pressure. A report from SBU, the Swedish Council on Technology Assessment in Health Care.Journal of internal medicine. Supplement, 737
J Intern Med, 238
Zethraeus N, Molin T, Henriksson P, Jönsson B (Stockholm School of Economics, Stockholm; and Södertälje Hospital, Södertälje; Sweden). Costs of coronary heart disease and stroke: the case of Sweden. J Intern Med 1999; 246: 151–159. Objectives. To estimate the annual costs in Sweden of coronary heart disease (CHD) and stroke, and the potential cost savings if these clinical ‘events’ are avoided. The analysis is undertaken from a societal perspective, including both direct and indirect costs. Costs are calculated for five clinical conditions : (i) acute myocardial infarction (AMI), (ii) angina pectoris (AP), (iii) unstable angina (UA), (iv) congestive heart failure (CHF), and (v) stroke. Design. A retrospective study including patients admitted to the Department of Medicine at Södertälje Hospital during the period January 1993 to March 1995 with CHD or a stroke. Each patient was followed for 1 year after admission to the hospital. To estimate potential cost savings, the patient was used as his or her own control. The potential savings in direct costs if CHD or a stroke is avoided were estimated as the difference between costs for 1 year after and 1 year before the event. The indirect costs were calculated as the difference between the values of market production of goods and services the year before the event and the year after. Setting. The Department of Medicine at Södertälje Hospital, Södertälje, Sweden. Subjects. The patients included in the study were patients at the Department of Medicine at Södertälje Hospital in Sweden. The inclusion criterion was that the patients should have been admitted for the first time for CHD or stroke during the year 1994. To obtain 25 patients for each clinical category we first had to expand the inclusion period to cover January 1993 to March 1995. Secondly, we also had to include 36 patients with an earlier established uncomplicated CHD or stroke. Despite this, no more than 22 patients with UA were found. Interventions. Patients were followed in medical practice. Main outcome measures. Costs, direct and indirect costs, and potential savings. Results. The mean direct costs during the year after a clinical event range between Swedish kronor (SEK) 41 000 for CHF and SEK 96 000 for stroke, whereas the mean potential savings in direct costs range from SEK 36 000 for CHF to SEK 91 000 for UA. The potential mean savings in indirect costs range between SEK 24 000 for CHF and SEK 102 000 for AMI. The direct costs for first‐time patients are lower than those for patients with an earlier established CHD or stroke. No systematic differences have been found in potential direct cost savings and indirect costs between the two patient groups. Conclusions. CHD and stroke are associated with high costs during the year after admission to the Department of Medicine. There are also large potential cost savings from the prevention of CHD and stroke. However, further studies, including more patients and costs arising in the municipality, are needed to establish more precise and complete estimates of the costs related to CHD and stroke.
Journal of Internal Medicine – Wiley
Published: Aug 1, 1999
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.